A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus

A critical aspect of the treatment of most patients with type 2 diabetes mellitus (T2DM) is the initiation (and subsequent intensification) of insulin therapy when lifestyle interventions and oral anti-hyperglycaemic drugs fail to maintain or improve glycaemic control. There are several insulin treatment options available, including basal insulin, basal-bolus insulin and premixed insulin. Each of these options has advantages and disadvantages. The insulin lispro premixed insulin analogues, mix 25 (25% insulin lisproand 75% insulin lispro protamine suspension) and mix 50 (50% insulin lispro and 50% insulin lispro protamine suspension), which include intermediate- and rapid-acting components, were recently added to Russia’s national drug reimbursement program, increasing the treatment options for patients with T2DM. The aim of this review is to provide Russian physicians with current information on the efficacy and safety of insulin lispro, with a focus on insulin lispro mixtures, for the treatment of T2DM.

1. Дедов И.И., Шестакова М.В., Сунцов Ю.И., и др. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007-2012 годы» // Сахарный диабет. – 2013. – Т. 16. – №2S – C. 1-48. [Dedov II, Shestakova MV, Suntsov YI, et al. Federal targeted programme “Prevention and Management of Socially Significant Diseases (2007-2012)”: results of the “Diabetes mellitus” sub-programme. Diabetes mellitus. 2013;16(2S):1-48. (in Russ)] doi: 10.14341/2072-0351-3879.

2. Дедов И.И. От истоков эндокринологии к достижениям ХХI века. VII Всероссийский диабетологический конгресс, 24-28 февраля 2015. [Dedov II. Ot istokov endokrinologii k dostizheniyam XXIveka. VII Russian Diabetology Congress, 24-28 Feb 2015. (In Russ)]

3. Сунцов Ю.И., Маслова О.В., Дедов И.И. Скрининг осложнений сахарного диабета как метод оценки лечебно-профилактической помощи больным // Проблемы эндокринологии. — 2010. — Т. 56. — №1. — С. 3-8. [Suntsov II, Maslova OV, Dedov II. Screening for diabetic complications as a tool for the evaluation of medical and preventive aid to patients. Probl Endokrin (Mosk). 2010;56(1):3-8. (In Russ)]

4. International Diabetes Federation. IDF Diabetes Atlas, 6th ed. Brussels: International Diabetes Federation; 2014.

5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853. doi: 10.1016/S0140-6736(98)07019-6

6. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: 10.1056/NEJMoa0806470.

7. Elizarova S, Galstyan GR, Wolffenbuttel BH. Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: a narrative review. J Diabetes. 2014;6(2):100-110. doi: 10.1111/1753-0407.12096.

8. Tambascia MA, Nery M, Gross JL, et al. Evidence-based clinical use of insulin premixtures. Diabetol Metab Syndr. 2013;5(1):50. doi: 10.1186/1758-5996-5-50.

9. Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009;52(10):1990-2000. doi: 10.1007/s00125-009-1468-7.

10. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 7-й выпуск. Москва. Министерство здравоохранения РФ. 2015.

11. Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32(6):1007-1013. doi: 10.2337/dc08-2117.

12. Buse JB, Wolffenbuttel BH, Herman WH, et al. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care. 2011;34(2):249-255. doi: 10.2337/dc10-1701.

13. Yamasaki K, Nishiyama H, Imaoka T. Comparing the efficacy and safety of insulin lispro Mix25 BID and insulin glargine as starter insulin in oral antihyperglycemic agents failure patients with type 2 diabetes – subgroup analysis by body mass index (BMI) at baseline to evaluate the efficacy of two starter insulins for blood glucose profiles (DURABLE trial). Prog Med. 2014;34:1595-1605.

14. Jovanovic L, Peters AL, Jiang HH, Hardin DS. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes. Aging Clin Exp Res.2014;26(2):115-121. doi: 10.1007/s40520-013-0140-8.

15. Bowering K, Reed VA, Felicio JS, et al. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. Diabet Med. 2012;29(9):e263-272. doi: 10.1111/j.1464-5491.2012.03722.x.

16. Tinahones FJ, Gross JL, Onaca A, et al. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes Metab. 2014;16(10):963-970. doi: 10.1111/dom.12303.

17. Miser WF, Arakaki R, Jiang H, et al. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther. 2010;32(5):896-908. doi: 10.1016/j.clinthera.2010.05.001.

18. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2007;29(11):2349-2364. doi: 10.1016/j.clinthera.2007.11.016.

19. Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31(1):20-25. doi: 10.2337/dc07-1122.

20. Edelman SV, Liu R, Johnson J, Glass LC. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care.2014;37(8):2132-2140. doi: 10.2337/dc13-2664.